Ispinesib
- Generic Name
- Ispinesib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H33ClN4O2
- CAS Number
- 336113-53-2
- Unique Ingredient Identifier
- BKT5F9C2NI
- Indication
Investigated for use/treatment in breast cancer, lung cancer, solid tumors, renal cell carcinoma, pediatric indications, ovarian cancer, and head and neck cancer.
- Associated Conditions
- -
- Associated Therapies
- -
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 15
- Registration Number
- NCT00095992
- Locations
- π¨π¦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
π¨π¦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
π¨π¦Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2
Completed
- Conditions
- Stage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the OropharynxStage IV Verrucous Carcinoma of the LarynxStage IV Verrucous Carcinoma of the Oral CavityMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the Larynx
- Interventions
- First Posted Date
- 2004-11-08
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00095628
- Locations
- π¨π¦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
Study Of Ispinesib In Subjects With Breast Cancer
- First Posted Date
- 2004-08-20
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00089973
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-06-17
- Last Posted Date
- 2010-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00085813
- Locations
- π¬π§
GSK Investigational Site, Sutton, Surrey, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2024. All Rights Reserved by MedPath